Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.260
+0.110 (3.49%)
At close: Aug 11, 2026, 4:00 PM EDT
3.251
-0.009 (-0.29%)
After-hours: Aug 11, 2026, 7:52 PM EDT
Prime Medicine Employees
Prime Medicine had 146 employees as of December 31, 2025. The number of employees decreased by 68 or -31.78% compared to the previous year.
Employees
146
Change (1Y)
-68
Growth (1Y)
-31.78%
Revenue / Employee
$27,897
Profits / Employee
-$1,286,932
Market Cap
579.97M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 146 | -68 | -31.78% |
| Dec 31, 2024 | 214 | -20 | -8.55% |
| Dec 31, 2023 | 234 | 59 | 33.71% |
| Dec 31, 2022 | 175 | 74 | 73.27% |
| Sep 30, 2022 | 150 | 86 | 134.38% |
| Jun 30, 2022 | 137 | 73 | 114.06% |
| Mar 31, 2022 | 101 | - | - |
| Sep 30, 2021 | 64 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Ginkgo Bioworks Holdings | 485 |
| 4D Molecular Therapeutics | 196 |
| MapLight Therapeutics | 133 |
| Adlai Nortye | 109 |
| Artiva Biotherapeutics | 106 |
| Silence Therapeutics | 88 |
| Contineum Therapeutics | 51 |
PRME News
- 5 days ago - Prime Medicine reports Q4 EPS (24c), consensus (26c) - TheFly
- 5 days ago - Prime Medicine Quarterly report: Q2 2026 - Filings
- 5 days ago - Prime Medicine Earnings release: Q2 2026 - Filings
- 19 days ago - Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease - GlobeNewsWire
- 4 weeks ago - TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647 - TheFly
- 4 weeks ago - Resolution in favor of Prime has limited impact to Beam, says BofA - TheFly
- 4 weeks ago - Prime Medicine reports positive resolution to arbitration with Beam Therapeutics - TheFly
- 4 weeks ago - Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics - GlobeNewsWire